Home Biotech Chinese Immune Cell Gene Therapy Start-up Secured $85 Million

Chinese Immune Cell Gene Therapy Start-up Secured $85 Million

Immune Cell Therapy

Kenneth Lim of the Business Times reports that Suzhou China-based Gracell Biotechnologies has raised $85 million through a series B round led by Temasek Holdings—a Singapore government investment house.  Other participants included Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji. Gracell focuses on developing modified immune cells—T-cells. They will use the proceeds to enter into the complex and expensive clinical trial phase for a number of its next-generation treatment candidates. According to Mr. Kim the company has already accomplished a number of pre-clinical development milestones involving a series of low-cost Chimeric Antigen Receptors T cell (CAR T) therapy products. They have entered institutional review board (IRB) clinical research.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.